- Home
- EVAX vs IMNN Comparison
EVAX vs IMNN Comparison
Compare EVAX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- IMNN
- Stock Information
- Founded
- EVAX 2008
- IMNN 1982
- Country
- EVAX Denmark
- IMNN United States
- Employees
- EVAX N/A
- IMNN N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- IMNN Health Care
- Exchange
- EVAX Nasdaq
- IMNN Nasdaq
- Market Cap
- EVAX 15.1M
- IMNN 12.1M
- IPO Year
- EVAX 2021
- IMNN 1985
- Fundamental
- Price
- EVAX $2.61
- IMNN $8.50
- Analyst Decision
- EVAX Strong Buy
- IMNN Buy
- Analyst Count
- EVAX 2
- IMNN 2
- Target Price
- EVAX $10.00
- IMNN $210.00
- AVG Volume (30 Days)
- EVAX 121.3K
- IMNN 429.5K
- Earning Date
- EVAX 08-13-2025
- IMNN 08-05-2025
- Dividend Yield
- EVAX N/A
- IMNN N/A
- EPS Growth
- EVAX N/A
- IMNN N/A
- EPS
- EVAX N/A
- IMNN N/A
- Revenue
- EVAX $3,293,000.00
- IMNN N/A
- Revenue This Year
- EVAX N/A
- IMNN N/A
- Revenue Next Year
- EVAX N/A
- IMNN N/A
- P/E Ratio
- EVAX N/A
- IMNN N/A
- Revenue Growth
- EVAX 2555.64
- IMNN N/A
- 52 Week Low
- EVAX $1.20
- IMNN $5.55
- 52 Week High
- EVAX $17.75
- IMNN $47.40
- Technical
- Relative Strength Index (RSI)
- EVAX 49.56
- IMNN 43.13
- Support Level
- EVAX $2.56
- IMNN $6.51
- Resistance Level
- EVAX $3.03
- IMNN $9.18
- Average True Range (ATR)
- EVAX 0.20
- IMNN 1.27
- MACD
- EVAX -0.01
- IMNN 0.34
- Stochastic Oscillator
- EVAX 25.00
- IMNN 36.25
About EVAX Evaxion Biotech
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).